Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 14/20 | 0.64 |
| ▸ | GRK2 | P25098 | 13/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | PRKCA | P17252 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | GRK3 | P35626 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14195576 | 0.81 | ROCK2 (0.58) | ROCK2GRK2MAPTMEN1KMT2A | |
| SCHEMBL8320877 | 0.80 | POLB (0.57) | ROCK2GRK2MAPTMEN1KMT2A | |
| SCHEMBL14195573 | 0.79 | ROCK2 (0.53) | ROCK2GRK2MAPTMEN1KMT2A | |
| SCHEMBL14195577 | 0.78 | ROCK2 (0.53) | ROCK2GRK2MAPTMEN1KMT2A | |
| SCHEMBL4864431 | 0.70 | XBP1 (0.53) | ROCK2GRK2MAPTMEN1KMT2A | |
| SCHEMBL25260290 | 0.70 | CSNK1D (0.49) | ROCK2GRK2MAPTMEN1KMT2A | |
| SCHEMBL4868681 | 0.69 | POLB (0.54) | MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL31063668 | 0.69 | GRK2 (0.80) | ROCK2GRK2PRKCAGRK3 | |
| SCHEMBL4873541 | 0.69 | SMN1; SMN2 (0.52) | MAPTMEN1KMT2APRKCASMN1; SMN2 | |
| SCHEMBL4789027 | 0.69 | PDE10A (0.46) | ROCK2GRK2PRKCAGRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361669-B2 | Compositions and method for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | claimed |
| US-7361669-B2 | Compositions and method for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361669-B2 | Compositions and method for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361669-B2 | Compositions and method for inhibiting TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-20040157861-A1 | Compositions and methods for inhibiting TGF-beta | MILLENNIUM PHARMACEUTICALS, INC. | 2004-08-12 | — | — | US | disclosed |
| WO-2004060362-A2 | COMPOSITIONS AND METHODS FOR INHIBITING TGF-β | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157861-A1 | Compositions and methods for inhibiting TGF-beta | TGFB1, TGFB2, TGFBR1 | ROCK2 583/4885GRK2 1152/4885MAPT 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.